Spotlight On... Exit stage left for senior leaders at Intrexon; FDA approves new anthrax therapy; Aveo gets $134M deal for AV-203; Newly merged Vyriad focuses on oncolytics; and more...

Intrexon ($XON) has announced the departure of its chief operating officer, Krish Krishnan, and SVP of product development Suma Krishnan, effective immediately. The Virginia-based firm, which focuses on synthetic biology, said in a statement this was because of the "successful growth of the company"--and also because it has also hired new senior members to run the five business sectors across the company. The two roles will now be spread among a number of existing officers, with Joel Liffmann, SVP of finance, taking on primary responsibility for operating divisions. Randal Kirk, chairman and CEO of Intrexon, said: "I would like to thank Krish and Suma for their contributions to the company." Release

@FierceBiotech: Atlantic Healthcare closes $24M round and gains Salix founder as new CSA. News | Follow @FierceBiotech

@JohnCFierce: Biotech startup trendsetters at Arch hunting up $400M-plus for venture fund. Report | Follow @JohnCFierce

> The FDA approved Elusys' anthrax treatment Anthim (obiltoxaximab), which is used with antibacterials. The biotech developed the drug with help from BARDA, which is backing a range of new bioterrorism-related therapies. Release

> Aveo Oncology snagged a $1 million upfront from Beijing-based CANbridge life sciences for an Asian licensing pact for AV-203, AVEO's clinical-stage ErbB3 (HER3) antibody candidate. Aveo is also in line for up to $133 million in milestones. Release

> Omnis Pharma and Magnis Therapeutics are merging into Vyriad, a clinical-stage oncolytic immunovirotherapy development company. Release

Medical Device News

@FierceMedDev: ICYMI Friday: J&J highlights consumer devices, most investable 6 device segments in quest for growth. Article | Follow @FierceMedDev

@EmilyWFierce: ICYMI from FiercePharma: Senators lambaste Turing for 'unethical' price hikes at latest drug price hearing. Report | Follow @EmilyWFierce

> Med tech consultant discusses China FDA, tries to clear up Chinese clinical trial confusion. Editor's corner

> J&J moves to settle swath of lawsuits over power morcellator devices: WSJ. More

> FDA warns of potential for poor video quality when using Verathon's recalled video laryngoscopes. Article

Pharma News

@FiercePharma: Elanco debuts immune-boosting cow drug at USDA confab on antibiotic alternatives. More from FierceAnimalHealth | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: First came the recall, then the FDA plant ban, now the warning letter to Emcure plant for faking data. Story | Follow @EricPFierce

@CarlyHFierce: Starting Monday off wrong--watching tons of graphic shingles commercials. | Follow @CarlyHFierce

> Valeant heeds calls for new CEO, links iffy financials to hard-charging 'tone at the top.' Story

> J&J, BMS are delivering solid sales from new meds. The rest of Big Pharma, not so much: Forbes. Report

> NICE does a U-turn on J&J's Zytiga for pre-chemo after drugmaker offers cost-cutting deal. Article

Pharma Marketing News

> Marketers aren't spending enough on ads, researcher says. And yes, that includes pharma. Story

> Pharma's doctor payments do pay off, with more money yielding more scripts: Pro Publica. Article

> Switching study gives Celltrion biosim more ammo in fight for Remicade share. Report

> NICE changes its tune on J&J's Zytiga for pre-chemo prostate cancer treatment. Item

> Note to pharma: Stop fishing social media one hook at a time. A trawler net works much better. More

Animal Health News

> Pet owners boost medication purchases amid record $60B-plus spending: Story

> Five questions for One Health Company founder Ben Lewis. Report

> Elanco debuts immune-boosting cow drug at USDA confab on antibiotic alternatives. Article

> U.K. scientists launch study of emerging tick-borne disease in dogs. Item

> Embark Veterinary launches DNA testing kit for dogs with research applications in mind. More

Biotech IT News

> Following on from GSK deal, WNS adds data analytics capabilities in $17.5M buyout. News

> IMS creates Hootsuite app to help pharma manage social media compliance. Report

> 10x Genomics scoops another $55M to fuel commercialization of long-read tech. Article

> Huawei, WuXi team up to power the China Precision Medicine Initiative. Story

> Zealand, BioSolveIT pool resources to develop peptide design tool. More

Suggested Articles

Frontage is Growing to Meet All Your Needs! Click Here to Learn About the Next Generation of Frontage.

Cara Care, a digital health startup focused on digestive diseases, raised $7 million to bring its mobile app to more patients in the U.S.

Investors looked past the headline success of Sci-B-Vac, zeroed in on the failure to achieve a secondary objective and sent VBI’s stock down 66%.